Mini-GRID radiotherapy limits cellular senescence in glioma models

A new research paper was recently published in Volume 18 of Aging, titled "Spatially fractionated mini-GRID radiotherapy differentially modulates radiation-induced senescence in murine glioma and normal cells."

The study found that spatially fractionated mini-GRID radiotherapy reduced several features of radiation-induced cellular senescence in two glioma cell lines while maintaining an antiproliferative effect comparable to conventional radiotherapy. In non-tumor cell models, however, the two radiation approaches produced similar senescence responses.

The research was led by equal-contributing first authors M. Isabel Acuña and Miguel Ángel Prados, both affiliated with the University of Santiago de Compostela. Corresponding authors Manuel Collado and Yolanda Prezado are also affiliated with the University of Santiago de Compostela. Collado is additionally affiliated with the National Centre for Biotechnology (CNB-CSIC), while Prezado is additionally affiliated with the Oportunius Program of the Galician Agency of Innovation (GAIN), Xunta de Galicia.

Radiotherapy remains a cornerstone of cancer treatment, but it can also push surviving cells into senescence, a state of persistent cell-cycle arrest. Senescent cells can develop a senescence-associated secretory phenotype (SASP), releasing inflammatory and other signaling molecules that affect surrounding tissues and the tumor microenvironment. Although senescence can restrict tumor-cell proliferation, persistent therapy-induced senescence may also contribute to inflammation, treatment resistance and other adverse effects.

Spatially fractionated radiotherapy (SFRT) differs from conventional radiotherapy by delivering radiation in a deliberately non-uniform pattern, creating high-dose "peaks" separated by lower-dose "valleys." The researchers investigated whether mini-GRID, a form of SFRT, produces different senescence responses from conventional uniform irradiation.

The study compared the two approaches in F98 and RG2 rat glioma cells, immortalized rat astrocytes and primary mouse embryonic fibroblasts. Cells received single radiation doses ranging from 5 to 20 Gy and were evaluated seven days later using morphological, biochemical and molecular measures of senescence.

At 20 Gy, conventional and mini-GRID radiotherapy produced comparable reductions in glioma cell numbers. Their effects on senescence, however, differed substantially. Conventional radiotherapy increased cell size and senescence-associated β-galactosidase activity, while these changes were significantly attenuated following mini-GRID irradiation.

The molecular results reinforced this difference. Conventional radiotherapy increased senescence and persistent DNA-damage markers, including p53, p21, p16 and γH2AX. Mini-GRID irradiation reduced their accumulation, with levels approaching those of non-irradiated controls. It also markedly reduced the induction of SASP-related genes. Il1a, Il6 and Serpine1 were strongly induced by conventional irradiation but remained closer to baseline after mini-GRID treatment, while Cxcl1 showed a more cell-line-specific response.

The researchers propose that this difference may arise from mini-GRID's spatial dose distribution. High-dose peaks can produce lethal damage in directly exposed cells, while lower-dose valleys may allow surviving cells to repair damage without fully activating a stable senescence program. This mechanism remains a proposed explanation and requires further investigation.

Importantly, the pattern differed in non-tumor cells. In immortalized astrocytes and mouse embryonic fibroblasts, radiation induced senescence in a dose-dependent manner, but no significant differences were detected between conventional and mini-GRID irradiation at matched doses. Under the experimental conditions tested, mini-GRID therefore attenuated senescence in glioma cells without increasing senescence relative to conventional radiation in the non-tumor models.

"These observations indicate that spatially fractionated mini-GRID RT can alter the qualitative nature of radiation-induced stress responses in tumor cells without exacerbating senescence in healthy tissues."

The findings could have important implications because therapy-induced senescence can act as a double-edged sword. While it can prevent damaged cells from continuing to divide and contribute to antitumor immune responses, persistent senescent cells and their SASP can also promote inflammation and alter the tumor microenvironment. Preserving radiation-induced tumor-cell reduction while limiting persistent senescence could therefore represent a useful biological advantage.

However, the study is preclinical. Experiments were performed using a limited number of rodent cell models grown in two-dimensional culture, with single radiation doses, one mini-GRID configuration and measurements at a single time point. The study also did not evaluate long-term SASP dynamics or interactions with immune and other components of the tumor microenvironment. Three-dimensional and in vivo studies will be necessary to determine whether these effects persist in more complex biological systems.

Overall, the findings show that mini-GRID radiotherapy can preserve the growth-inhibitory effects of radiation while reducing senescence, persistent DNA-damage signaling and SASP activation in glioma cells. The results support further investigation of how spatial radiation delivery could improve the therapeutic balance between tumor control and unwanted long-term cellular responses.